All patients
metastasis (liver ) previous nephrectomy (no) previous nephrectomy (yes) Risk favorable (IMDC) Risk favorable (MSKCC) Risk intermediate (IMDC) Risk intermediate (MSKCC) Risk poor (IMDC) Risk poor (MSKCC)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
renal cell cancer (RCC), atezolizumab plus bevacizumab vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias progression or deaths (PFS)detailed results IMmotion-150 (AtB - all population), 2018 1.00 [0.69; 1.45]
IMmotion-150 (AtB - PDL1>1%), 2018 0.64 [0.38; 1.08]
0.83 [0.54 ; 1.28 ] IMmotion-150 (AtB - all population), 2018, IMmotion-150 (AtB - PDL1>1%), 2018 2 46% 312 moderate not evaluable objective responses (ORR)detailed results IMmotion-150 (AtB - all population), 2018 1.15 [0.63; 2.10]
IMmotion-150 (AtB - PDL1>1%), 2018 2.34 [1.05; 5.20]
1.56 [0.78 ; 3.11 ] IMmotion-150 (AtB - all population), 2018, IMmotion-150 (AtB - PDL1>1%), 2018 2 48% 312 moderate not evaluable AE (any grade)detailed results IMmotion-150 (AtB - all population), 2018 2.03 [0.07; 61.21]
2.03 [0.07 ; 61.21 ] IMmotion-150 (AtB - all population), 2018 1 0% 201 NA not evaluable AE (grade 3-4)detailed results IMmotion-150 (AtB - all population), 2018 0.78 [0.43; 1.40]
0.78 [0.43 ; 1.40 ] IMmotion-150 (AtB - all population), 2018 1 0% 201 NA not evaluable AE leading to death (grade 5)detailed results IMmotion-150 (AtB - all population), 2018 1.50 [0.25; 9.17]
1.50 [0.25 ; 9.17 ] IMmotion-150 (AtB - all population), 2018 1 0% 201 NA not evaluable TRAE (any grade)detailed results IMmotion-150 (AtB - all population), 2018 0.38 [0.11; 1.25]
0.38 [0.11 ; 1.25 ] IMmotion-150 (AtB - all population), 2018 1 0% 201 NA not evaluable TRAE (grade 3-4)detailed results IMmotion-150 (AtB - all population), 2018 0.49 [0.28; 0.87]
0.49 [0.28 ; 0.87 ] IMmotion-150 (AtB - all population), 2018 1 0% 201 NA not evaluable TRAE leading to death (grade 5)detailed results IMmotion-150 (AtB - all population), 2018 0.49 [0.04; 5.49]
0.49 [0.04 ; 5.49 ] IMmotion-150 (AtB - all population), 2018 1 0% 201 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMmotion-150 (AtB - all population), 2018 0.99 [0.02; 50.39]
0.99 [0.02 ; 50.39 ] IMmotion-150 (AtB - all population), 2018 1 0% 201 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMmotion-150 (AtB - all population), 2018 0.99 [0.02; 50.39]
0.99 [0.02 ; 50.39 ] IMmotion-150 (AtB - all population), 2018 1 0% 201 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-20 22:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 10,93,79,178,152,80
- treatments: 602
